(continued)
- Aqvesme: FDA Approves First Pill for Treating Anemia in Adults With Alpha- or Beta- Thalassemia
- Accrufer: FDA Expands Use of Oral Iron Treatment for Kids Ages 10 and Older
- Lunsumio Velo: FDA Approves a Convenient Under-the-Skin Shot for Relapsed or Refractory Follicular Lymphoma
- FDA Approves Once-Daily Wegovy Pill as the First Oral GLP-1 Medicine for Weight Loss in Adults With Obesity or Overweight
- FDA Approves Rybrevant Faspro: An Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer
- FDA Approves Akeega for Metastatic Prostate Cancer
- Cardamyst: FDA Approves Nasal Spray for Sudden Fast Heartbeats
- FDA Approves Nuzolvence for Drug-Resistant Gonorrhea
- Waskyra: First Gene Therapy for Wiskott-Aldrich Syndrome
- FDA Approves Breyanzi: First and Only CAR T-Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma
- Imfinzi: FDA Approves New Treatment Option for Early, Resectable, and Locally Advanced Gastric and Gastroesophageal Junction Cancers
- Voyxact: FDA Grants Accelerated Approval to Once-Monthly Injection for Adults With IgA Nephropathy
- Itvisma: FDA Approves One-Time Gene Therapy for Spinal Muscular Atrophy in Children 2 or Older, Teens, and Adults
- Keytruda and Padcev: FDA Approves New Combination Therapy for Aggressive Bladder Cancer
- Koselugo: FDA Approves Second Oral Treatment for Adults With Neurofibromatosis Type 1
- FDA Approves Redemplo to Lower Triglycerides
- FDA Approves Ziftomenib: First Once-Daily Oral Therapy for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
- Darzalex Faspro: A New Treatment for High-Risk Smoldering Multiple Myeloma
- Caplyta: A New Add-On Option for Adults With Depression
- Linzess: First Drug Approved for Children and Adolescents With IBS-C
- Kygevvi: FDA Approves First Oral Treatment for Thymidine Kinase 2 Deficiency (TK2d)
- Blenrep Combination Therapy Approved by FDA for Relapsed or Refractory Multiple Myeloma
- Lynkuet (Elinzanetant): A New Nonhormonal Treatment for Menopausal Hot Flashes and Sleep Disturbances
- FDA Approves Combined Use of Zepzelca and Atezolizumab as First-Line Maintenance Treatment for Advanced Small-Cell Lung Cancer
- Rhapsido: A New Oral Option for Chronic Spontaneous Urticaria
- FDA Approves Enbumyst: First and Only Nasal Spray Diuretic for Edema From Heart, Liver, and Kidney Diseases
- Opzelura: FDA Expands Use of Steroid-Free Skin Cream for Young Children With Eczema
- Ocaliva Pulled From U.S. Market for Liver Disease
- Inlexzo: A New Bladder Cancer Treatment
- FDA Expands Approved Use of Vonvendi